• 415 Capital Management portfolio company R3 Vascular named Robert Spanos VP, Global Market Development, to support trial enrollment and commercialization planning.
• Katie Segreto appointed VP, Finance and Corporate Controller, as the company scales operations and prepares for future market launch.
• Management changes announced Aug. 24, 2026, alongside continued development of MAGNITUDE bioresorbable scaffolds for peripheral arterial disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 415 Capital Management GmbH published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.